Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.45 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.36 |
| ▸ | ACLY | P53396 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31503298 | 0.94 | SIRT6 (0.45) | SIRT6SOS1CA2CA1CA5A | |
| SCHEMBL31568318 | 0.94 | SIRT6 (0.45) | SIRT6SOS1CA2CA1CA5A | |
| SCHEMBL20501221 | 0.83 | POLB (0.43) | CDK1TSHRLMNAGAAMAPT | |
| SCHEMBL20501193 | 0.82 | CFTR (0.38) | SIRT6SOS1CA2CA1CA5A | |
| SCHEMBL29991315 | 0.82 | SOS1 (0.40) | SIRT6SOS1CA2CA1CA5A | |
| SCHEMBL31394743 | 0.80 | SOS1 (0.51) | SIRT6SOS1CA2CA1CA9 | |
| SCHEMBL19682396 | 0.80 | GAA (0.42) | CDK1TSHRGAAMAPTPOLB | |
| SCHEMBL21865574 | 0.80 | PKM (0.47) | CA2CA1CA5ACA9CDK1 | |
| SCHEMBL29835245 | 0.80 | PKM (0.47) | CA2CA1CA5ACA9CDK1 | |
| SCHEMBL1044961 | 0.79 | SOS1 (0.46) | SIRT6SOS1CA2CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4587438-A1 | BICYCLIC COMPOUNDS AS CDK INHIBITORS | BeiGene Switzerland GmbH (CH) | 2025-07-23 | — | — | EP | disclosed |
| CN-119894890-A | Bicyclic compounds as CDK inhibitors | 百济神州(苏州)生物科技有限公司 | 2025-04-25 | — | — | CN | disclosed |
| US-20230373940-A1 | CARBOXYLIC DIARYLTHIAZEPINEAMINES AND USES THEREOF | KURES, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230373940-A1 | CARBOXYLIC DIARYLTHIAZEPINEAMINES AND USES THEREOF | KURES, INC. | 2023-11-23 | — | — | US | disclosed |
| US-11787772-B2 | Carboxylic diarythiazepineamines as mixed mu- and delta-opioid receptor agonists | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787772-B2 | Carboxylic diarythiazepineamines as mixed mu- and delta-opioid receptor agonists | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-10-17 | — | — | US | disclosed |
| WO-2022074589-A1 | CARBOXYLIC DIARYLTHIAZEPINEAMINES AND USES THEREFOR | KURES, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| US-20200079745-A1 | CARBOXYLIC DIARYTHIAZEPINEAMINES AS MIXED MU-AND DELTA-OPIOID RECEPTOR AGONISTS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-03-12 | — | — | US | disclosed |
| WO-2018170275-A1 | CARBOXYLIC DIARYTHIAZEPINEAMINES AS MIXED MU-AND DELTA-OPIOID RECEPTOR AGONISTS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2018-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787772-B2 | Carboxylic diarythiazepineamines as mixed mu- and delta-opioid receptor agonists | OPRD1, OPRM1, OPRK1 | SIRT6 4335/4885SOS1 1960/4885CA2 2430/4885 |
| US-20200079745-A1 | CARBOXYLIC DIARYTHIAZEPINEAMINES AS MIXED MU-AND DELTA-OPIOID RECEPTOR AGONISTS | OPRD1, OPRM1, OPRK1 | SIRT6 4335/4885SOS1 1960/4885CA2 2430/4885 |
| US-20230373940-A1 | CARBOXYLIC DIARYLTHIAZEPINEAMINES AND USES THEREOF | CDKL5, KMT5A, CDKL1 | SIRT6 800/4885SOS1 2417/4885CA2 3202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.